Saved in:
| Main Author: | |
|---|---|
| Format: | Recurso digital |
| Language: | |
| Published: |
Zenodo
2026
|
| Online Access: | https://doi.org/10.5281/zenodo.18206286 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- <blockquote> <p>Abstract</p> </blockquote> <p>Cancer-associated venous thromboembolism (VTE) represents a significant clinical challenge</p> <p>due to its high incidence and recurrence risk. Apixaban, a direct oral anticoagulant (DOAC), has</p> <p>emerged as a promising option for both acute and extended treatment phases. This article</p> <p>evaluates the efficacy and safety of extended low-dose apixaban (2.5 mg twice daily) for the</p> <p>long-term management of cancer-associated VTE, drawing on clinical trials, observational</p> <p>studies, and mechanistic insights. We discuss dosing strategies, patient selection criteria,</p> <p>bleeding risks, and the role of imaging in monitoring outcomes. The findings suggest that low-</p> <p>dose apixaban offers a favorable balance of efficacy and safety, reducing recurrent VTE while</p> <p>minimizing major bleeding events in cancer patients. Recommendations for clinical practice and</p> <p>future research are provided.</p> <p>Keywords: Cancer-associated VTE, apixaban, low-dose anticoagulation, extended therapy,</p> <p>bleeding risk, imaging.</p>